The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours
E Kelly, SJ Mundell, A Sava, AL Roth, A Felici… - …, 2015 - Springer
Rationale The novel opioid receptor antagonist, GSK1421498, has been shown to attenuate
reward-driven compulsive behaviours, such as stimulant drug seeking or binge eating, in …
reward-driven compulsive behaviours, such as stimulant drug seeking or binge eating, in …
Investigating the Potential of Novel Bivalent Pharmacophores and Tetra-Branched Opioids to Produce Analgesics with Diminished Tolerance and Dependence …
MF Bird - 2015 - figshare.le.ac.uk
All clinical opioid analgesics target the MOP (Mu Opioid Peptide) receptor. While these
drugs provide analgesia, long-term treatment leads to tolerance and dependence. By …
drugs provide analgesia, long-term treatment leads to tolerance and dependence. By …